Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Irbm-science Park S.p.a.

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

C.n.c.c.s. Scarl Collezione Nazionale Dei Composti Chimici E Centro Screening

Istituto Di Ricerche Di Biologia P. Angeletti S.p.a.

Msd Italia S.r.l.

Emanuela Nizi

Vincenzo Summa

Paola Pace

Alessia Petrocchi

Marco Poma

Cristina Gardelli

Michael Rowley

Rita Scarpelli

Steven Harper

Ester Muraglia

Federica Orvieto

Giovanna Pescatore

Benedetta Crescenzi

Maria Emilia Di Francesco

Victor Giulio Matassa

Barbara Pacini

Edith Monteagudo

Ralph Laufer

Sergio Altamura

Alberto Bresciani

Ester Murgalia

Jesus Maria Ontoria Ontoria

Roberto Gambari

Federica Ferrigno

Simona Ponzi

Savina Malancona

Giacomo Paonessa

Ilaria Biancofiore

Maria Vittoria Orsale

Maria Veneziano

Giulia Breveglieri

Danilo Fabbrini

The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like &#x3b2;-thalassemia or sickle cell anemia. 

Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC

The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.

Compounds for use in the treatment of parasitic diseases

The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R, R, R, R, R, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Macrocyclic compounds as antiviral agents

N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R, R, Rand Rare defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase

4,5-Dihydroxypyrimidine-6-carboxamides of formula:  are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R, R, Rand Rare defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Dihydroxypyrimidine carboxamide inhibitors of HIV integrase

4,5-Dihydroxypyrimidine-6-carboxamides of formula (I); are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R, R, Rand Rare defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described 

N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R, R, Rand Rare defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds-are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R, R, Rand Rare defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described 

Growing community of inventors

Siena, Italy

Emanuela Nizi